PT - JOURNAL ARTICLE AU - Law, Steven AU - Petrie, Aviva AU - Chacko, Liza AU - Cohen, Oliver C AU - Ravichandran, Sriram AU - Gilbertson, Janet A AU - Rowczenio, Dorota AU - Wechalekar, Ashutosh D AU - Martinez-Naharro, Ana AU - Lachmann, Helen J AU - Whelan, Carol J AU - Hutt, David F AU - Hawkins, Philip N AU - Fontana, Marianna AU - Gillmore, Julian D TI - Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy AID - 10.1136/heartjnl-2021-319063 DP - 2022 Mar 01 TA - Heart PG - 474--478 VI - 108 IP - 6 4099 - http://heart.bmj.com/content/108/6/474.short 4100 - http://heart.bmj.com/content/108/6/474.full SO - Heart2022 Mar 01; 108 AB - Objectives Wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) is a progressive and fatal condition. Although prognosis can be determined at the time of diagnosis according to National Amyloidosis Centre (NAC) transthyretin amyloidosis (ATTR) stage, the clinical course varies substantially between individuals. There are currently no established measures of rate of disease progression. Through systematic analysis of functional, biochemical and echocardiographic disease-related variables we aimed to identify prognostic markers of disease progression in wtATTR-CM.Methods This is a retrospective observational study of 432 patients with wtATTR-CM diagnosed at the UK NAC, none of whom received disease-modifying therapy. The association between mortality from the 12-month timepoint and change from diagnosis to 12 months in a variety of disease-related variables was explored using Cox regression.Results Change in N-terminal pro-B-type natriuretic peptide concentration (∆ NT-proBNP) at 12 months from diagnosis was the strongest predictor of ongoing mortality and was independent of both change in other disease-related variables (HR 1.04 per 500 ng/L increase (95% CI 1.01 to 1.07); p=0.003) and a range of known prognostic variables at the time of diagnosis (HR 1.07 per 500 ng/L increase (95% CI 1.02 to 1.13); p=0.007). An increase in NT-proBNP of >500 ng/L, >1000 ng/L and >2000 ng/L during the first year of follow-up occurred in 45%, 35% and 16% of patients, respectively.Conclusion Change in NT-proBNP concentration during the first year of follow-up is a powerful independent predictor of mortality in wtATTR-CM.Data are available upon reasonable request.